TY - JOUR
T1 - Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab
T2 - could it represent a marker of treatment efficacy?
AU - Menzella, Francesco
AU - Latorre, Manuela
AU - Ruggiero, Patrizia
AU - Bagnasco, Diego
AU - Heffler, Enrico
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Subjects with severe Th2-high endotype usually respond to oral corticosteroids (OCS). However, they often require high dosages with incremental side effects and health-care costs. The advent of biological therapies provides an effective strategy to improve asthma control, as well as reduce OCS use. Various molecules have been developed, each targeting different pathways. We analyzed the two anti-IL-5 strategies, benralizumab and mepolizumab, based on pivotal trials (RCTs), mechanisms of action and their possible role on the steroid-sparing effect. Areas covered: This review analyzes the data from the benralizumab and mepolizumab RCTs, focusing on the advantages of each drug on clinical efficacy and the steroid-sparing effect. Expert opinion: Benralizumab may represent a promising therapeutic option in the treatment of eosinophilic asthma, due to its mechanism of action, which rapidly allows a reduction in the eosinophils’ number, and a greater steroid-sparing effect.
AB - Introduction: Subjects with severe Th2-high endotype usually respond to oral corticosteroids (OCS). However, they often require high dosages with incremental side effects and health-care costs. The advent of biological therapies provides an effective strategy to improve asthma control, as well as reduce OCS use. Various molecules have been developed, each targeting different pathways. We analyzed the two anti-IL-5 strategies, benralizumab and mepolizumab, based on pivotal trials (RCTs), mechanisms of action and their possible role on the steroid-sparing effect. Areas covered: This review analyzes the data from the benralizumab and mepolizumab RCTs, focusing on the advantages of each drug on clinical efficacy and the steroid-sparing effect. Expert opinion: Benralizumab may represent a promising therapeutic option in the treatment of eosinophilic asthma, due to its mechanism of action, which rapidly allows a reduction in the eosinophils’ number, and a greater steroid-sparing effect.
KW - eosinophils
KW - Oral corticosteroids
KW - randomized clinical trials
KW - severe asthma
KW - side effects
UR - http://www.scopus.com/inward/record.url?scp=85066271839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066271839&partnerID=8YFLogxK
U2 - 10.1080/14712598.2019.1613367
DO - 10.1080/14712598.2019.1613367
M3 - Article
C2 - 31033373
AN - SCOPUS:85066271839
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
ER -